Epstein-Barr virus downregulates breast cancer gene 1 to facilitate GPX4-dependent ferroptosis resistance and tumor growth of B-cell lymphoma
Blocking a specific protein restores cancer-fighting cell death in EBV-infected lymphomas, identifying a potential therapeutic target for this virus-associated cancer.
This study identified that EBV promotes B-cell lymphoma progression via EBNA1-driven BRCA1 downregulation, which prevents GPX4 autophagy-mediated degradation and confers ferroptosis resistance. Knockdown of GPX4 in EBV-positive cells restored ferroptosis sensitivity and markedly suppressed xenograft tumor growth, identifying the BRCA1-GPX4 axis as a potential therapeutic target in EBV-associated lymphoma.
What the study was
- Study design
- Preclinical mechanistic study with EBV+ B-cell lymphoma cell lines and xenograft models
- Population
- EBV-positive B-cell lymphoma cell lines and xenograft mouse models
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Int J Biol Macromol
Why it surfaced
Novel EBV-BRCA1-GPX4 ferroptosis resistance mechanism in B-cell lymphoma; preclinical only (cell lines + xenograft); no primary patient cells; mechanistic novelty high but clinical translation early.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.